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Reply to: ‘‘TERT promoter mutation during development
of hepatoblastoma to hepatocellular carcinoma’’
To the Editor:
With interest we read the letter by Dong et al., bringing up
important points on the role of telomerase reverse-transcriptase
(TERT) promoter mutations in paediatric liver tumours, which we
would like to comment.
First of all, we like to emphasize that hepatoblastoma (HB)
and their progenies with hepatocellular carcinoma (HCC)-like
features, the so-called transitional liver cell tumours (TLCTs),
are full-blown malignant tumours that develop in young
children, characteristically without cirrhosis or underlying liver
disease. Although HCCs do also occur in older children, they most
often lack the cirrhotic background found in 90% of HCC in adults
[1], at least in Western countries.
One of the concerns raised by Dong et al. related to our results
showing TERT promoter mutations in 2/4 TLCT cases, but not in
any HB (0/43), although both tumour types displayed elevated
TERT expression levels and typically harbour ß-catenin (CTNNB1)
mutations [2]. Recent work clearly indicates that TERT promoter
mutations qualify as the earliest genetic event in the multistep
process of carcinogenesis in the adult liver, as they are already
found to some extent in preneoplastic lesions and then regularly
in HCC [3], both in virally associated tumours as well as in cases
without any underlying liver disease or cirrhosis [4]. In line with
this, TERT promoter mutations were observed in a high percent-
age of stage I well-differentiated HCC [4], but not in classical
adenomas [5]. Strikingly, TERT expression was signiﬁcantly
upregulated in all HCC cases, being mutated or wild type, as com-
pared to normal liver and hepatocellular adenoma [3]. Thus, it
seems that TERT upregulation needs to be re-acquired for the
development of HCC in adults because of its origin from differen-
tiated cells that do not cycle anymore, and that CTNNB1 muta-
tions add on to this in a later phase [6]. In contrast, the high
telomerase activity of HB and TLCTs in children might result from
the physiological state and high self-renewal capacity of liver
precursor cells, from which they develop, and TERT promoter
mutations are not necessarily needed for the malignant transfor-
mation, which is presumably driven only by Wnt activation. Nev-
ertheless, TERT promoter mutations display a selective
phenomenon of TLCTs, which might be used as a marker for the
detection of high-risk patients.
Concerning our conclusion that TLCTs are rather a genetically
derailed progeny of HB than an early onset HCC, we are fully
aware that we have analysed only four TLCT cases, which by
the way is a respectable number with worldwide seven TLCT
cases being published so far [7]. Nevertheless, we discuss ample
characteristics that TLCTs display a neoplastic continuation
along an ontogenetic differentiation pathway from HB to HCC,
including the CTNNB1 status, AFP serum levels, histology, chro-
mosomal imbalances, and survival rates [2]. Moreover, we
postulate that mutations in gate keeper genes, such as RAD17,
MSH6, and TP53 are responsible for the development of an
advanced tumour type with chromosomal instability and higher
mutation rates.
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Open access under CC BY-NC-ND license.The identiﬁcation of glypican 3 (GPC3) by microarray analysis
as a gene highly overexpressed in HB and HCC [8] has certainly
improved the diagnosis of liver tumours. Subsequent immuno-
histochemical studies revealed that HB are consistently positive
(100%) for GPC3, whereas HCCs were positive only in 56–84%,
and dysplastic nodules were consistently negative [6,9,10].
Interestingly, GPC3 positivity was inversely associated with the
differentiation of HCCs into poorly (100%), moderately (83%)
and well-differentiated (78%) HCCs [10]. However, GPC3 immu-
nostaining was not helpful in paediatric HCC [11]. By analysing
our TLCT cases by immunohistochemistry, we regularly found
strong GPC3 positivity in all tumours (Fig. 1), indicating that it
more likely reﬂects the situation of HB than paediatric or adult
HCC. Considering the lack of TERT promoter mutations in HB,
the strong association between TERT promoter mutations and
positive GPC3 immunostaining found by Nault et al. [6] might
be statistically signiﬁcant, but not necessarily biologically
relevant.
Altogether, we feel that it is safe to predict that TLCTs display
a neoplastic continuation along an ontogenetic differentiation
pathway from HB to HCC, and that both are characterized by
unique features that set them aside from HCC, both in children
and adults. Nevertheless, the idea of Dong et al. of investigating
paediatric HCCs to clarify the role of TERT promoter mutations
is highly appreciated, especially in view of prooﬁng that paediat-
ric HCC is another disease than HCC in adults.Conﬂict of interest
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Fig. 1. Immunohistological staining of glypican 3 in a transitional liver cell
tumour.
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Ferritin in decompensated cirrhosis: Iron or inﬂammation?
To the Editor:
In a recent article, Maiwall and colleagues describe serum ferritin
as a predictor of mortality in patients with decompensated cirrho-
sis. The authors conclude that the association between elevated
serum ferritin and mortality may have therapeutic implications
[1].
Elevated serum ferritin is commonly seen in many causes of
chronic liver disease and is thought to relate to hepatic iron over-
load or inﬂammation, or a combination of both. Indeed, in the
absence of systemic inﬂammation, serum ferritin is an excellent
marker of body iron stores, such as is seen in hereditary haemo-
chromatosis, a frequent cause of hepatic iron excess [2]. Alcoholic
and non-alcoholic fatty liver disease and chronic viral hepatitis
are associated with hepatic inﬂammation and mild to moderate
hepatic iron accumulation, making serum ferritin less interpret-
able. Distinguishing the cause of hyperferritinaemia is an often
encountered clinical issue.
Although it has been widely accepted that damaged hepato-
cytes are the main source of circulating ferritin, Cohen et al.
recently revealed that a major contribution occurs from macro-
phages [3]. In the context of decompensated cirrhosis and acute-
on-chronic liver failure, where the importance of macrophage
activation is well recognized [4], this ﬁnding is of relevance. The
addition of C-reactive protein (CRP) measurement in this study
would help to clarify the driver of hyperferritinaemia, indeed
CRP has been shown to predict short-term survival in patients
with cirrhosis and acute-on-chronic liver failure [5,6].
As hepatic synthetic dysfunction progresses in end stage liver
disease, reduced production of hepcidin, the liver-derived iron
regulatory hormonemay occur [7,8]. Hepcidinmay be further sup-
pressed by oxidative stress, which is prevalent in decompensated
cirrhosis [9,10]. Deﬁcient hepcidin production leads to elevated
iron absorption, hyperferritinaemia and hepatic iron deposition,
which would exacerbate the original insult. No comment is made
on the potential value of serum hepcidin measurements in these
patients. Furthermore, the authors do not provide transferrin sat-
uration levels, which, if raised, would indicate iron overload as a
contributing factor.
In summary, whileMaiwall and colleagues provide an interest-
ing addition to the predictors of outcome in patients with decom-
pensated cirrhosis, further information would be of value in order
to guide therapeutic strategies and future research in this area.
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